Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia

Leukemia

Volumn 29, Issue 2, 2015, Pages 491-494

  Fordham, S E ^a   Cole, M ^a   Irving, J A ^a   Allan, J M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; THYMIDINE KINASE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CELL DEATH; CELL POPULATION; DNA REPLICATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; INDUCED MUTATION; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MISMATCH REPAIR; MUTAGENICITY; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SOMATIC MUTATION; ALGORITHM; CHEMISTRY; GENETICS; LEUKEMIA, MYELOID, ACUTE; MONTE CARLO METHOD; MUTATION; REMISSION; TUMOR CELL LINE; TUMOR RECURRENCE;

ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CYTARABINE; DNA MUTATIONAL ANALYSIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MONTE CARLO METHOD; MUTATION; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION;

EID: 84922464023     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.284     Document Type: Letter

References (11)

1. Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C et al. Cytarabine dose for acute myeloid leukemia. N Engl Journal Med 2011; 364: 1027-1036.
2. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494.
3. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
4. Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011; 118: 3803-3810.
5. Graham FL, Whitmore GF. Studies in mouse L-cells on the incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-beta-D-arabinofuranosylcytosine 5'-triphosphate. Cancer Res 1970; 30: 2636-2644.
6. Zahn RK, Muller WE, Forster W, Maidhof A, Beyer R. Action of 1-β-D-arabinofuranosylcytosine on mammalian tumor cells. 1. Incorporation into DNA. Eur J Cancer 1972; 8: 391-396.
7. Liber HL, Thilly WG. Mutation assay at the thymidine kinase locus in diploid human lymphoblasts. Mutat Res 1982; 94: 467-485.
8. Fordham SE, Matheson EC, Scott K, Irving JA, Allan JM. DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs. Leukemia 2011; 25: 1046-1049.
9. de Wind N, Dekker M, Berns A, Radman M, te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 1995; 82: 321-330.
10. Gao YG, van der Marel GA, van Boom JH, Wang AH. Molecular structure of a DNA decamber containing an anticancer nucleoside arabinosylcytosine: conformational perturbation by arabinosylcytosine in B-DNA. Biochemistry 1991; 30: 9922-9931.
11. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. New Engl J Med 2012; 366: 1090-1098.